Holen Sie sich die Stockscreener-App
183.50
0.72%
-1.405
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$184.90
Offen:
$185.99
24-Stunden-Volumen:
504.72K
Relative Volume:
0.31
Marktkapitalisierung:
$26.93B
Einnahmen:
$9.53B
Nettoeinkommen (Verlust:
$1.29B
KGV:
20.84
EPS:
8.8057
Netto-Cashflow:
$1.97B
1W Leistung:
-0.71%
1M Leistung:
-6.59%
6M Leistung:
+26.72%
1J Leistung:
+31.13%
1-Tages-Spanne:
$183.10
$188.00
1-Wochen-Bereich:
$182.60
$192.99
52-Wochen-Spanne:
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
183.51 | 27.14B | 9.53B | 1.29B | 1.97B | 8.8057 |
|
LLY
Lilly Eli Co
|
984.81 | 872.68B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.00 | 583.29B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
219.90 | 398.49B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
190.06 | 298.53B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
153.35 | 294.33B | 54.72B | 14.02B | 15.32B | 7.1855 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference - Yahoo Finance
Assessing Biogen (BIIB) Valuation After Recent Shareholder Return Momentum - simplywall.st
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders - BioSpace
Biogen’s Spinraza successor benefits SMA patients unresponsive to gene therapy - Yahoo
Swiss National Bank Cuts Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander Effective May 2026 - Minichart
Biogen Announces Upcoming Departure of Chief Legal Officer - TipRanks
Biogen chief legal officer Susan H. Alexander to depart at end of May - Investing.com
Oppenheimer reiterates Biogen stock rating on SMA drug data - Investing.com
Biogen Unveils Phase III Salanersen Program To Bring Longer-Acting SMA Option - Citeline News & Insights
Biogen builds case for Spinraza successor with fresh data - BioPharma Dive
To promote Zurzuvae, Biogen and Supernus are Turning Tides against postpartum depression - Medical Marketing and Media
Biogen Stock: Is BIIB Outperforming the Healthcare Sector? - Barchart.com
Biogen Settles Investors' $50M Claim Over Pain Drug Deal - Law360
Biogen presents additional salanersen data in SMA - The Pharma Letter
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock - Yahoo Finance
Biogen (BIIB) Reveals Promising Phase 1b Study Results for Salan - GuruFocus
Van ECK Associates Corp Has $149.46 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen presents new Phase 1b results for spinal muscular atrophy drug at MDA Conference - Traders Union
Biogen presents Phase 1b data on salanersen for SMA treatment - Investing.com
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy - Biogen
Biogen to Participate in the Stifel 2026 Virtual CNS Forum - Biogen
Therapeutics Sector Q4 2025 Earnings Review: Resilience and GrowthNews and Statistics - IndexBox
Causeway Capital Management LLC Acquires 74,163 Shares of Biogen Inc. $BIIB - MarketBeat
Jefferies Financial Group Inc. Cuts Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks - The Globe and Mail
Down 36% intraday BIIB.SW Biogen Inc. (SIX) 09 Mar 2026: catalysts to track - Meyka
MDA 2026: Trio of trials now testing Spinraza successor salanersen for SMA - SMA News Today
Rhenman & Partners Asset Management AB Boosts Biogen Stake by 358% - National Today
Rhenman & Partners Asset Management AB Has $7.70 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen’s Dravet And SMA Advances Add Depth To Long Term Story - simplywall.st
Biogen CEO touts “new era of growth” at TD Cowen as 10 Phase 3 programs near key readouts - MarketBeat
Biogen Inc (BIIB) Shares Gap Down to $181.74 on Mar 6 - GuruFocus
Health Rounds: Protein related to Parkinson's linked to faster Alzheimer's progression in women - marketscreener.com
Biogen/Stoke’s zorevunersen hailed as potential first disease-modifying drug for rare epilepsy - European Pharmaceutical Review
Spinal muscular atrophy research progresses at 2026 MDA Conference, Biogen asserts - Traders Union
What Makes Biogen (BIIB) an Attractive Long-Term Holding? - Insider Monkey
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences - Biogen
Biogen Inc Announces to Present New Data and Updates from Its Spinal Muscle Atrophy Research Programs - marketscreener.com
(BIIB) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Mo - PharmiWeb.com
Biogen (BIIB) Reports Promising Data on Zorevunersen for Dravet Syndrome - GuruFocus
Stoke Therapeutics and Biogen Announce Promising Results for Zorevunersen in Treating Dravet Syndrome, Supporting Phase 3 EMPEROR Study - Quiver Quantitative
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome - Biogen
New drug hints at changing the course of Dravet syndrome - Stock Titan
Elo Mutual Pension Insurance Co Boosts Biogen Stake - National Today
BIIB Earnings History & Surprises | EPS & Revenue Results | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Evaluating Alzheimer's Disease Treatments - Seeking Alpha
Biogen Inc. $BIIB Shares Sold by Fisher Asset Management LLC - MarketBeat
Biogen : to Participate in the Leerink Global Healthcare Conference 2026 - marketscreener.com
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):